Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery

The recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) is a potent and selective brain serotonin (5-HT) neurotoxin in animals and, possibly, in humans. The purpose of the present study was to determine whether brain 5-HT deficits persist in squirrel monkeys beyond the 18-month period studied previously and to identify factors that influence recovery of injured 5-HT axons. Seven years after treatment, abnormal brain 5-HT innervation patterns were still evident in MDMA-treated monkeys, although 5-HT deficits in some regions were less severe than those observed at 18 months. No loss of 5-HT nerve cell bodies in the rostral raphe nuclei was found, indicating that abnormal innervation patterns in MDMA-treated monkeys are not the result of loss of a particular 5-HT nerve cell group. Factors that influence recovery of 5-HT axons after MDMA injury are (1) the distance of the affected axon terminal field from the rostral raphe nuclei, (2) the degree of initial 5-HT axonal injury, and possibly (3) the proximity of damaged 5-HT axons to myelinated fiber tracts. Additional studies are needed to better understand these and other factors that influence the response of primate 5-HT neurons to MDMA injury and to determine whether the present findings generalize to humans who use MDMA for recreational purposes.

[1]  E. Azmitia,et al.  The primate serotonergic system: a review of human and animal studies and a report on Macaca fascicularis. , 1986, Advances in neurology.

[2]  M. Wilson,et al.  (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. , 1988, JAMA.

[3]  T. Insel,et al.  Neurotoxic Effects of MDMA on Brain Serotonin Neurons: Evidence from Neurochemical and Radioligand Binding Studies a , 1990, Annals of the New York Academy of Sciences.

[4]  C. J. Schmidt,et al.  Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.

[5]  A. Björklund,et al.  REGENERATION OF SEROTONIN NEURONS IN THE RAT BRAIN AFTER 5,6‐DIHYDROXYTRYPTAMINE‐INDUCED AXOTOMY * , 1978, Annals of the New York Academy of Sciences.

[6]  G. Battaglia,et al.  MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons , 1988, Pharmacology Biochemistry and Behavior.

[7]  A. Parent,et al.  Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey , 1990, The Journal of comparative neurology.

[8]  G. Ricaurte,et al.  Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  E. Azmitia,et al.  Regeneration of serotonergic fibers in the rat hypothalamus following unilateral 5,7-dihydroxytryptamine injection , 1984, Brain Research.

[10]  Rudy M. Baum,et al.  New Variety of Street Drugs Poses Growing Problem: Designer drugs—analogs of compounds with proven pharmacological activity made by underground chemists—present novel challenges to law enforcement officials, legislators, and scientists , 1985 .

[11]  G. Schneider.  Early Lesions of Superior Colliculus: Factors Affecting the Formation of Abnormal Retinal Projections; pp. 91–109 , 1973 .

[12]  G. Ricaurte,et al.  Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.

[13]  J. Langston,et al.  Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration , 1988, Brain Research.

[14]  Patrick M. O'Malley,et al.  National Survey Results on Drug Use from the Monitoring the Future Study, 1975-1998. Volume I: Secondary School Students. , 1999 .

[15]  K. Akert,et al.  A stereotaxic atlas of the brain of the squirrel monkey : (Saimiri sciureus) , 1963 .

[16]  M. Wilson,et al.  Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine , 1989, Neuroscience.

[17]  E. Azmitia,et al.  MDMA (ecstasy) effects on cultured serotonergic neurons: evidence for Ca2+-dependent toxicity linked to release , 1990, Brain Research.

[18]  C. J. Schmidt,et al.  Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. , 1987, Biochemical pharmacology.

[19]  B. Kosofsky,et al.  The serotoninergic innervation of cerebral cortex: Different classes of axon terminals arise from dorsal and median raphe nuclei , 1987, Synapse.

[20]  Y. Shaham,et al.  Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans , 1994, Neuropsychopharmacology.

[21]  G. Battaglia,et al.  Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  J. Richards,et al.  Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. , 1996, The Journal of pharmacology and experimental therapeutics.

[23]  G. Schneider.  Early lesions of superior colliculus: factors affecting the formation of abnormal retinal projections. , 1973, Brain, behavior and evolution.

[24]  J. Richards,et al.  Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[25]  A. Beaudet,et al.  Ultrastructural organization of regenerated serotonin axons in the dorsomedial hypothalamus of the adult rat , 1987, Journal of neurocytology.

[26]  W. Slikker,et al.  Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). , 1988, Toxicology and applied pharmacology.

[27]  Paul D. MacLean,et al.  A stereotaxic atlas of the squirrel monkey's brain (Saimiri sciureus) / , 1962 .

[28]  J L Katz,et al.  Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[29]  B. Jacobs,et al.  Structure and function of the brain serotonin system. , 1992, Physiological reviews.

[30]  M. Molliver,et al.  Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5‐HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives , 1991, The Journal of comparative neurology.

[31]  M. Wilson,et al.  Neurotoxicity of MDMA and Related Compounds: Anatomic Studies a , 1990, Annals of the New York Academy of Sciences.

[32]  E. Azmitia,et al.  The ultrastructural localization of serotonin immunoreactivity in myelinated and unmyelinated axons within the medial forebrain bundle of rat and monkey , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  T. Insel,et al.  3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. , 1989, The Journal of pharmacology and experimental therapeutics.

[34]  C. Altar,et al.  Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  E. D. De Souza,et al.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, Journal of Pharmacology and Experimental Therapeutics.

[36]  G. Hanson,et al.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. , 1986, European journal of pharmacology.

[37]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[38]  A. Björklund,et al.  Regeneration and plasticity of central serotoninergic neurons: a review. , 1981, Journal de physiologie.

[39]  I. Törk,et al.  Distribution of two morphologically distinct subsets of serotoninergic axons in the cerebral cortex of the marmoset , 1990, The Journal of comparative neurology.

[40]  L. Seiden,et al.  Long-term effects of chronic methamphetamine administration in rhesus monkeys , 1989, Brain Research.

[41]  U. McCann,et al.  Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. , 1994, The Journal of pharmacology and experimental therapeutics.

[42]  A. Björklund,et al.  Mechanisms of regrowth of the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. I. Biochemical correlates , 1980, Brain Research.

[43]  A. Björklund,et al.  Mechanisms of regrowth in the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. II. Fluorescence histochemical observations , 1980, Brain Research.

[44]  J. Contrera,et al.  Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data. , 1990, The Journal of pharmacology and experimental therapeutics.

[45]  L S Seiden,et al.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.